|
1
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swinnen JV, Van Veldhoven PP, Timmermans
L, De Schrijver E, Brusselmans K, Vanderhoydonc F, van de Sande T,
Heemers H, Heyns W and Verhoeven G: Fatty acid synthase drives the
synthesis of phospholipids partitioning into detergent-resistant
membrane microdomains. Biochem Biophys Res Commun. 302:898–903.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li J, Dong L, Wei D, Wang X, Zhang S and
Li H: Fatty acid synthase mediates the epithelial-mesenchymal
transition of breast cancer cells. Int J Biol Sci. 10:171–180.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Flavin R, Peluso S, Nguyen PL and Loda M:
Fatty acid synthase as a potential therapeutic target in cancer.
Future Oncol. 6:551–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hung CM, Kuo DH, Chou CH, Su YC, Ho CT and
Way TD: Osthole suppresses hepatocyte growth factor (HGF)-induced
epithelial-mesenchymal transition via repression of the
c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food
Chem. 59:9683–9690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vazquez-Martin A, Colomer R, Brunet J,
Lupu R and Menendez JA: Overexpression of fatty acid synthase gene
activates HER1/HER2 tyrosine kinase receptors in human breast
epithelial cells. Cell Prolif. 41:59–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burgess AW: EGFR family: Structure
physiology signalling and therapeutic targets. Growth Factors.
26:263–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lindsey S and Langhans SA: Epidermal
growth factor signaling in transformed cells. Int Rev Cell Mol
Biol. 314:1–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menendez JA, Vellon L and Lupu R:
Targeting fatty acid synthase-driven lipid rafts: A novel strategy
to overcome trastuzumab resistance in breast cancer cells. Med
Hypotheses. 64:997–1001. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ravacci GR, Brentani MM, Tortelli T Jr,
Torrinhas RS, Saldanha T, Torres EA and Waitzberg DL: Lipid raft
disruption by docosahexaenoic acid induces apoptosis in transformed
human mammary luminal epithelial cells harboring HER-2
overexpression. J Nutr Biochem. 24:505–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moulder SL, Yakes FM, Muthuswamy SK,
Bianco R, Simpson JF and Arteaga CL: Epidermal growth factor
receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits
HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in
vivo. Cancer Res. 61:8887–8895. 2001.PubMed/NCBI
|
|
14
|
Arora A and Scholar EM: Role of tyrosine
kinase inhibitors in cancer therapy. J Pharmacol Exp Ther.
315:971–979. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia W, Gerard CM, Liu L, Baudson NM, Ory
TL and Spector NL: Combining lapatinib (GW572016), a small molecule
inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic
anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing
breast cancer cells. Oncogene. 24:6213–6221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roskoski R Jr: ErbB/HER protein-tyrosine
kinases: Structures and small molecule inhibitors. Pharmacol Res.
87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gullick WJ: The c-erbB3/HER3 receptor in
human cancer. Cancer Surv. 27:339–349. 1996.PubMed/NCBI
|
|
18
|
Gullick WJ: c-erbB-4/HER4: Friend or foe?
J Pathol. 200:279–281. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knowlden JM, Gee JM, Seery LT, Farrow L,
Gullick WJ, Ellis IO, Blamey RW, Robertson JF and Nicholson RI:
c-erbB3 and c-erbB4 expression is a feature of the endocrine
responsive phenotype in clinical breast cancer. Oncogene.
17:1949–1957. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fry WH, Kotelawala L, Sweeney C and
Carraway KL III: Mechanisms of ErbB receptor negative regulation
and relevance in cancer. Exp Cell Res. 315:697–706. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Omura S: The antibiotic cerulenin, a novel
tool for biochemistry as an inhibitor of fatty acid synthesis.
Bacteriol Rev. 40:681–697. 1976.PubMed/NCBI
|
|
22
|
Zhou C, Nitschke AM, Xiong W, Zhang Q,
Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, et al:
Proteomic analysis of tumor necrosis factor-alpha resistant human
breast cancer cells reveals a MEK5/Erk5-mediated
epithelial-mesenchymal transition phenotype. Breast Cancer Res.
10:R1052008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Salatino M, Schillaci R, Proietti CJ,
Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH and
Elizalde PV: Inhibition of in vivo breast cancer growth by
antisense oligodeoxynucleotides to type I insulin-like growth
factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and
p42/p44 MAPK signaling pathways but not modulation of progesterone
receptor activity. Oncogene. 23:5161–5174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rogers SJ, Harrington KJ, Rhys-Evans P,
O-Charoenrat P and Eccles SA: Biological significance of c-erbB
family oncogenes in head and neck cancer. Cancer Metastasis Rev.
24:47–69. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Banerjee S, Wang Z, Xu H, Zhang
L, Mohammad R, Aboukameel A, Adsay NV, Che M, Abbruzzese JL, et al:
Antitumor activity of epidermal growth factor receptor-related
protein is mediated by inactivation of ErbB receptors and nuclear
factor-kappaB in pancreatic cancer. Cancer Res. 66:1025–1032. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Clark PA, Iida M, Treisman DM, Kalluri H,
Ezhilan S, Zorniak M, Wheeler DL and Kuo JS: Activation of multiple
ERBB family receptors mediates glioblastoma cancer stem-like cell
resistance to EGFR-targeted inhibition. Neoplasia. 14:420–428.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Engelman JA, Zejnullahu K, Gale CM,
Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov
GN, Bradner JE, et al: PF00299804, an irreversible pan-ERBB
inhibitor, is effective in lung cancer models with EGFR and ERBB2
mutations that are resistant to gefitinib. Cancer Res.
67:11924–11932. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–9. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JW, Soung YH, Seo SH, Kim SY, Park CH,
Wang YP, Park K, Nam SW, Park WS, Kim SH, et al: Somatic mutations
of ERBB2 kinase domain in gastric, colorectal, and breast
carcinomas. Clin Cancer Res. 12:57–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ueno NT and Zhang D: Targeting EGFR in
triple negative breast cancer. J Cancer. 2:324–328. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang ZG, Wei JM, Qin CF, Hao K, Tian XD,
Xie K, Xie XH and Yang YM: Suppression of the epidermal growth
factor receptor inhibits epithelial-mesenchymal transition in human
pancreatic cancer PANC-1 cells. Dig Dis Sci. 57:1181–1189. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Holbro T, Beerli RR, Maurer F, Koziczak M,
Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions
as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor
cell proliferation. Proc Natl Acad Sci USA. 100:8933–8938. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stern DF: ERBB3/HER3 and ERBB2/HER2 duet
in mammary development and breast cancer. J Mammary Gland Biol
Neoplasia. 13:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J,
Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR,
Condeelis JS, et al: Phosphoinositide 3-kinase signaling is
critical for ErbB3-driven breast cancer cell motility and
metastasis. Oncogene. 31:706–715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Beji A, Horst D, Engel J, Kirchner T and
Ullrich A: Toward the prognostic significance and therapeutic
potential of HER3 receptor tyrosine kinase in human colon cancer.
Clin Cancer Res. 18:956–968. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ebbing EA, Steins A, Fessler E, Stathi P,
Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF
and van Laarhoven HWM: Esophageal adenocarcinoma cells and
xenograft tumors exposed to Erb-b2 receptor tyrosine kinase 2 and 3
inhibitors activate transforming growth factor beta signaling,
which induces epithelial to mesenchymal transition.
Gastroenterology. 153:63–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McEvoy LM, O'Toole SA, Spillane CD, Martin
CM, Gallagher MF, Stordal B, Blackshields G, Sheils O and O'Leary
JJ: Identifying novel hypoxia-associated markers of chemoresistance
in ovarian cancer. BMC Cancer. 15:5472015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Teixidó C, Marés R, Aracil M, Cajal Ramón
y S and Hernández-Losa J: Epithelial-mesenchymal transition markers
and HER3 expression are predictors of elisidepsin treatment
response in breast and pancreatic cancer cell lines. PLoS One.
8:e536452013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bruzzese F, Leone A, Rocco M, Carbone C,
Piro G, Caraglia M, Di Gennaro E and Budillon A: HDAC inhibitor
vorinostat enhances the antitumor effect of gefitinib in squamous
cell carcinoma of head and neck by modulating ErbB receptor
expression and reverting EMT. J Cell Physiol. 226:2378–2390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mill CP, Zordan MD, Rothenberg SM,
Settleman J, Leary JF and Riese DJ II: ErbB2 is necessary for ErbB4
ligands to stimulate oncogenic activities in models of human breast
cancer. Genes Cancer. 2:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bae JA, Kho DH, Sun EG, Ko YS, Yoon S, Lee
KH, Ahn KY, Lee JH, Joo YE, Chung IJ, et al: Elevated coexpression
of KITENIN and the ErbB4 CYT-2 isoform promotes the transition from
colon adenoma to carcinoma following APC loss. Clin Cancer Res.
22:1284–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Prickett TD, Agrawal NS, Wei X, Yates KE,
Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA and Samuels
Y: Analysis of the tyrosine kinome in melanoma reveals recurrent
mutations in ERBB4. Nat Genet. 41:1127–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wali VB, Gilmore-Hebert M, Mamillapalli R,
Haskins JW, Kurppa KJ, Elenius K, Booth CJ and Stern DF:
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic
mice reveal isoform-specific roles in mammary gland development and
carcinogenesis. Breast Cancer Res. 16:5012014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Imbert AM, Garulli C, Choquet E, Koubi M,
Aurrand-Lions M and Chabannon C: CD146 expression in human breast
cancer cell lines induces phenotypic and functional changes
observed in epithelial to mesenchymal transition. PLoS One.
7:e437522012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Y, Song L, Ni H, Sun L, Jiao W, Chen
L, Zhou Q, Shen T, Cui H, Gao T and Li J: ERBB4 acts as a
suppressor in the development of hepatocellular carcinoma.
Carcinogenesis. 38:465–473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gallo RM, Bryant IN, Mill CP, Kaverman S
and Riese DJ II: Multiple functional motifs are required for the
tumor suppressor activity of a constitutively-active ErbB4 mutant.
J Cancer Res Ther Oncol. 1:102013.PubMed/NCBI
|
|
49
|
Uberall I, Kolár Z, Trojanec R, Berkovcová
J and Hajdúch M: The status and role of ErbB receptors in human
cancer. Exp Mol Pathol. 84:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ghayad SE, Vendrell JA, Ben Larbi S,
Dumontet C, Bieche I and Cohen PA: Endocrine resistance associated
with activated ErbB system in breast cancer cells is reversed by
inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer.
126:545–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Suo Z, Emilsen E, Tveit KM and Nesland JM:
Type 1 protein tyrosine kinases in benign and malignant breast
lesions. Histopathology. 33:514–521. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Walker RA and Dearing SJ: Expression of
epidermal growth factor receptor mRNA and protein in primary breast
carcinomas. Breast Cancer Res Treat. 53:167–176. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
El-Rehim Abd DM, Pinder SE, Paish CE, Bell
JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI and Ellis IO:
Expression and co-expression of the members of the epidermal growth
factor receptor (EGFR) family in invasive breast carcinoma. Br J
Cancer. 91:1532–1542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Badovinac-Crnjevic T, Jakic-Razumovic J,
Podolski P, Pleština S, Sarčević B, Munjas R and Vrbanec D:
Significance of epidermal growth factor receptor expression in
breast cancer. Med Oncol. 28 Suppl 1:S121–S128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Porta R, Blancafort A, Casòliva G, Casas
M, Dorca J, Buxo M, Viñas G, Oliveras G and Puig T: Fatty acid
synthase expression is strongly related to menopause in early-stage
breast cancer patients. Menopause. 21:188–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Suo Z, Berner HS, Risberg B, Karlsson MG
and Nesland JM: Estrogen receptor-alpha and C-ERBB-4 expression in
breast carcinomas. Virchows Arch. 439:62–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Witton CJ, Reeves JR, Going JJ, Cooke TG
and Bartlett JM: Expression of the HER1-4 family of receptor
tyrosine kinases in breast cancer. J Pathol. 200:290–297. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Silva SD, Cunha IW, Younes RN, Soares FA,
Kowalski LP and Graner E: ErbB receptors and fatty acid synthase
expression in aggressive head and neck squamous cell carcinomas.
Oral Dis. 16:774–780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Long QQ, Yi YX, Qiu J, Xu CJ and Huang PL:
Fatty acid synthase (FASN) levels in serum of colorectal cancer
patients: Correlation with clinical outcomes. Tumour Biol.
35:3855–3859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lodge AJ, Anderson JJ, Gullick WJ, Haugk
B, Leonard RC and Angus B: Type 1 growth factor receptor expression
in node positive breast cancer: Adverse prognostic significance of
c-erbB-4. J Clin Pathol. 56:300–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lewis S, Locker A, Todd JH, Bell JA,
Nicholson R, Elston CW, Blamey RW and Ellis IO: Expression of
epidermal growth factor receptor in breast carcinoma. J Clin
Pathol. 43:385–389. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chiu CG, Masoudi H, Leung S, Voduc DK,
Gilks B, Huntsman DG and Wiseman SM: HER-3 overexpression is
prognostic of reduced breast cancer survival: A study of 4046
patients. Ann Surg. 251:1107–1116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fujiwara S, Ibusuki M, Yamamoto S,
Yamamoto Y and Iwase H: Association of ErbB1-4 expression in
invasive breast cancer with clinicopathological characteristics and
prognosis. Breast Cancer. 21:472–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lim ST, Yu JH, Park HK, Moon BI, Ko BK and
Suh YJ: A comparison of the clinical outcomes of patients with
invasive lobular carcinoma and invasive ductal carcinoma of the
breast according to molecular subtype in a Korean population. World
J Surg Oncol. 12:562014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zengel B, Yararbas U, Duran A, Uslu A,
Elıyatkın N, Demırkıran MA, Cengiz F, Şimşek C, Postacı H, Vardar E
and Durusoy R: Comparison of the clinicopathological features of
invasive ductal, invasive lobular, and mixed (invasive ductal +
invasive lobular) carcinoma of the breast. Breast Cancer.
22:374–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Grunt TW, Wagner R, Grusch M, Berger W,
Singer CF, Marian B, Zielinski CC and Lupu R: Interaction between
fatty acid synthase- and ErbB-systems in ovarian cancer cells.
Biochem Biophys Res Commun. 385:454–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Suda K, Tomizawa K and Mitsudomi T:
Biological and clinical significance of KRAS mutations in lung
cancer: An oncogenic driver that contrasts with EGFR mutation.
Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Stivarou T and Patsavoudi E: Extracellular
molecules involved in cancer cell invasion. Cancers (Basel).
7:238–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhan L, Xiang B and Muthuswamy SK:
Controlled activation of ErbB1/ErbB2 heterodimers promote invasion
of three-dimensional organized epithelia in an ErbB1-dependent
manner: Implications for progression of ErbB2-overexpressing
tumors. Cancer Res. 66:5201–5208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kiuchi T, Ortiz-Zapater E, Monypenny J,
Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B,
Rolfe DJ, et al: The ErbB4 CYT2 variant protects EGFR from
ligand-induced degradation to enhance cancer cell motility. Sci
Signal. 7:ra782014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Spears M, Taylor KJ, Munro AF, Cunningham
CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J and Bartlett JM: In
situ detection of HER2:HER2 and HER2:HER3 protein-protein
interactions demonstrates prognostic significance in early breast
cancer. Breast Cancer Res Treat. 132:463–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sergina NV, Rausch M, Wang D, Blair J,
Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine
kinase inhibitor therapy by the kinase-inactive HER3. Nature.
445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tomek K, Wagner R, Varga F, Singer CF,
Karlic H and Grunt TW: Blockade of fatty acid synthase induces
ubiquitination and degradation of phosphoinositide-3-kinase
signaling proteins in ovarian cancer. Mol Cancer Res. 9:1767–1779.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vazquez-Martin A, Fernandez-Real JM,
Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S,
Brunet J and Menendez JA: Fatty acid synthase activity regulates
HER2 extracellular domain shedding into the circulation of
HER2-positive metastatic breast cancer patients. Int J Oncol.
35:1369–1376. 2009.PubMed/NCBI
|
|
77
|
Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian
X, Liu J, Jiang X, Shen Y, Zhang L, et al: Expressions of fatty
acid synthase and HER2 are correlated with poor prognosis of
ovarian cancer. Med Oncol. 32:3912015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Mirschberger C, Schiller CB, Schräml M,
Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G,
Kolm I, et al: RG7116, a therapeutic antibody that binds the
inactive HER3 receptor and is optimized for immune effector
activation. Cancer Res. 73:5183–5194. 2013. View Article : Google Scholar : PubMed/NCBI
|
